# Hapten Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hapten-sciences

- Industry: Biotechnology
- Headquarters: Memphis, US
- Website: www.haptensciences.com
- Total disclosed funding: $1.2M
- Latest round: Seed (Jun 1, 2013)
- Investors on record: 1

## About

Hapten Sciences is a biopharmaceutical company dedicated to developing innovative solutions that address critical health challenges, focusing on early-stage product development targeting unmet medical needs globally.Founded in 2010 and based in Memphis, US, Hapten Sciences, Inc. specializes in biopharmaceuticals and has completed 7 deals to date. The most recent deal occurred on October 21, 2019, when it raised USD 0.88 mn in Venture Debt financing. The company is led by CEO Ray Hage, whose background includes experience in the biopharmaceutical sector.Hapten Sciences specializes in the development of innovative biopharmaceutical products aimed at addressing significant health challenges. The company focuses on early-stage product development that targets unmet medical needs, with an emphasis on enhancing human health and well-being globally. Their product offerings engage a diverse client base, including healthcare providers, pharmaceutical distributors, and research institutions, serving markets across North America, Europe, and Asia.Hapten Sciences generates revenue through partnerships and direct transactions with healthcare facilities, pharmaceutical wholesalers, and research organizations. The company's transaction framework is based on B2B models, facilitating the distribution of their biopharmaceutical products to various entities within the healthcare ecosystem. Revenue is derived from both initial product sales and ongoing collaborations, which may include subscription-based services for continuous supply or support.In October 2019, Hapten Sciences raised USD 0.88 mn in Venture Debt financing, which will be utilized to support the development of upcoming products and enhance operational capacity. The company aims to expand into new markets in North America, Europe, and Asia by 2025, focusing on launching innovative biopharmaceutical solutions that respond to emerging health needs.

## Funding rounds

- Seed, Jun 1, 2013, $0.5M — MB Venture Partners
- Seed, Jun 1, 2012, $0.7M — MB Venture Partners

## Investors

- MB Venture Partners (https://capitalatlas.ai/funds/mb-venture-partners) — Seed